VC-backed Carbylan Therapeutics rolls out IPO

Palo Alto, California-based Carbylan Therapeutics, a pharmaceutical company focused on developing treatments that “address significant unmet clinical needs,” has raised $65 million in its IPO after pricing its 13 million shares at $5 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “CBYL.” Leerink Partners LLC is serving as lead underwriter. The company’s backers included InterWest Partners, Alta Partners and Vivo Ventures.

VC-backed aTyr files for IPO

San Diego-based biotherapeutics company aTyr Pharma Inc has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. The company plans on trading its stock on the NASDAQ under the ticker symbol “LIFE.” J.P. Morgan Securities LLC and Citigroup Global Markets Inc will serve as the lead underwriters. The company’s backers include Alta Partners, Cardinal Partners, Domain Associates, Polaris Partners, Sofinnova Ventures, T. Rowe Price Associates Inc, Federated Investors Inc, Deerfield, Rock Springs Capital Management, EcoR1 Capital and Sphera Global Healthcare.

177 Views

Allakos secures $10 mln

Biotechnology company Allakos has secured an additional $10 million investment from current investors to fund the development of an additional therapeutic antibody. All of the company’s current investors participated including Novo Ventures, Alta Partners, RiverVest Venture Partners and the Roche Venture Fund.

VC-backed Kite Pharma unveils IPO

Kite Pharma has launched its IPO after pricing its 7.5 million shares at $17 per share. The stock began trading Friday on the NASDAQ under the ticker symbol “KITE.” Jefferies, Credit Suisse Securities (USA) and Cowen and Company are the lead underwriters. Based in Santa Monica, Calif., Kite Pharma is a biopharmaceutical firm focused on treating cancer. Kite Pharma’s backers include Alta Partners and TPG Capital.

VC-backed Zafgen raises $96 mln for IPO

Zafgen has debuted its IPO after pricing its 6 million shares at $16 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “ZFGN.” Leerink Partners and Cowen and Company are the lead underwriters. Based in Cambridge, Mass., Zafgen is a biopharmaceutical company focused on treating severely obese patients. Zafgen’s investors include RA Capital Management, Brookside Capital, Venrock and Alta Partners.

108 Views

VC-backed Kite Pharma files for IPO

Kite Pharma has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. Jefferies, Credit Suisse Securities (USA) and Cowen and Company are serving as the lead underwriters. Based in Santa Monica, Calif., Kite Pharma is a biopharmaceutical firm focused on treating cancer. Kite Pharma’s backers include Alta Partners and TPG Capital.

Shire acquires VC-backed Lumena Pharmaceuticals

Shire has acquired Lumena Pharmaceuticals. No financial terms were disclosed. Citi provided financial advice to Lumena. Based in San Diego, Lumena is a biopharmaceutical company focused on rare cholestatic liver diseases and serious metabolic disorders. Its backers include New Enterprise Associates, Adage Capital Management, RA Capital Management, Pappas Ventures, RiverVest Venture Partners and Alta Partners.

VC-backed Zafgen nabs $20 mln from Oxford and MidCap Financial

Zafgen has secured a $20 million loan from Oxford and MidCap Financial. Based in Cambridge, Mass., Zafgen is a biopharmaceutical company focused on treating severely obese patients. Zafgen’s investors include RA Capital Management, Brookside Capital, Venrock and Alta Partners.

Lumena attracts $45 mln in Series B funds

Lumena Pharmaceuticals said Tuesday that it has closed $45 million in Series B financing. New Enterprise Associates led the round with participation from Adage Capital Management, RA Capital Management, Pappas Ventures, RiverVest Venture Partners and Alta Partners. Based in San Diego, Lumena is a biopharmaceutical company focused on rare cholestatic liver diseases and serious metabolic disorders.

Kite Pharma Completes $35m Financing

Kite Pharma, a clinical stage biotechnology company focused on developing innovative targeted immunotherapies for cancer, has closed a $20 million private placement of shares of its Series A Preferred Stock. Joined by a new investor, Alta Partners, all existing major investors participated in the financing.

Kiadis Pharma Secures Financing

Kiadis Pharma, a clinical stage biopharmaceutical company developing treatments for blood cancers, has raised 10 million euros ($12.8 million) in an equity financing round. The round was led by Life Sciences Partners and supported by a large investment from DFJ-Esprit. Other investors included Alta Partners, Quest for Growth and NOM.

Sutro Biopharma Secures More Funds Led by Skyline Ventures

San Francisco-based Sutro Biopharma has closed a $16.5 million second tranche of its Series C financing. The financing was led by Skyline Ventures and included participation of Lilly Ventures, Amgen Ventures, SV Life Sciences and Alta Partners. Sutro has raised almost $60 million since its founding in 2003. PRESS RELEASE Sutro Biopharma today announced the […]

aTyr Pharma Appoints Board Member

Protein therapeutics company aTyr Pharma has appointed R. Alan Ezekowitz to aTyr’s Therapeutic advisory board. Physician scientist Dr. Ezekowitz has led various research and development programs at Merck. The privately-held biotech company was founded by The Scripps Research Institute Professor Paul Schimmel and is backed by life sciences investors Alta Partners, Cardinal Partners, Domain Associates […]

Pfizer Buys Excaliard Pharmaceuticals

Pfizer Inc. is buying Excaliard Pharmaceuticals Inc. for an undisclosed amount. Excaliard develops drugs for the treatment of skin fibrosis. Excaliard Pharmaceuticals previously raised venture financing from Alta Partners, ProQuest Investments and RiverVest Venture Partners.

SARcode Bioscience Inks $44M Series B

Brisbane, Calif.-based SARcode Bioscience has closed on $44 million in Series B financing, led by Sofinnova Ventures. Rho Ventures also participated, as did existing investors Alta Partners and Clarus Venture Partners. The money will go toward clinical development of the company’s treatment for dry eye syndrome.

Aerie Pharmaceuticals Closes $30M Series B

Aerie Pharmaceuticals Inc., a biotechnology company focused on medical innovations in ophthalmology, has closed $30 million in Series B financing. Clarus Ventures and Sofinnova Ventures co-led the round, with participation from Osage University Partners and existing investors Alta Partners and TPG Biotech. Aerie Pharmaceuticals has offices in Research Triangle Park, N.C. and in Bridgewater, N.J.

Gimv, Others Exit Investment in Plexxikon

Daiichi Sankyo has agreed to buy Plexxikon for $805 million, providing an exit for venture investors including Belgian firm GIMV. Future milestone payments could total an additional $130 million, the company said. Plexxikon develops novel small molecule pharmaceuticals to treat human disease. Gimv first invested in Plexxikon during a series B financing in 2002. The company is also backed by Alta Partners, ATV, Walden International, Pappas Ventures and CW Ventures.

PE HUB Community

Join the 12515 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget